Bayer announced that the US FDA has approved Gadavist (gadobutrol) injection for use in cardiac magnetic resonance imaging (CMRI) to assess myocardial perfusion and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD). The FDA approval is based on two prospective, open-label, non-randomized, multi-center, blinded-read phase III studies, which investigated the diagnostic results of gadobutrol-enhanced cardiac MRI for the evaluation of significant CAD. “Gadobutrol-enhanced cardiac MR demonstrated efficacy in a large global multicenter clinical trial,” said Daniel S. Berman, MD, FACC, Chief of Cardiac Imaging and Nuclear Cardiology at the Cedars-Sinai Heart Institute and the S. Mark Taper Foundation Imaging Center, Los Angeles, USA. “The FDA approval is a landmark for making this validated, non-invasive method available to healthcare professionals to evaluate their patients for the most common form of heart disease in the world.”
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!